CSL Behring GmbH (secondary packaging, batch release; manufacturing of solvent; production of finished medicinal product, primary packaging, quality control)
UkraineAll drugs from this manufacturer
-
The drug is used for the prevention and treatment of bleeding in patients with von Willebrand disease (if other methods are ineffective) and in hemophilia A. It can also be used to control acquired factor VIII deficiency and to treat patients with the presence of antibodies to this factor.
Dosage form: powder and solvent for solution for injection or infusion
Active substance Dosage human blood coagulation factor viii 250 IU or 50 IU/ml human von willebrand factor 600 IU or 120 IU/mL ATC: B02BD06
-
The drug is used for the prevention and treatment of bleeding in von Willebrand disease (if other methods are ineffective) and in hemophilia A. It may also be used to control acquired factor VIII deficiency.
Dosage form: powder and solvent for solution for injection or infusion
Active substance Dosage human blood coagulation factor viii 500 IU or 50 IU/mL human von willebrand factor 1200 IU or 120 IU/ml ATC: B02BD06
-
The drug is used for the prevention and treatment of bleeding in von Willebrand disease (if other methods are ineffective) and in hemophilia A. It can also be used to control acquired factor VIII deficiency and to treat patients with the presence of anti-factor VIII antibodies.
Dosage form: powder and solvent for solution for injection or infusion
Active substance Dosage human blood coagulation factor viii 1000 IU or 66.6 IU/ml human von willebrand factor 2400 IU or 160 IU/ml ATC: B02BD06